

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE der the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Application Number 10/539,256 Filing Date **TRANSMITTAL** (Int'l) November 25, 2003 First Named Inventor **FORM** Matthias WIESNER Art Unit 1626 (to be used for all correspondence after initial filing) Examiner Name S. Young

Total Number of Pages in This Submission		ion 7	Attorney Doc	ket Number	613242000800	
ENCLOSURES (Check all that apply)						
Fee Transmittal Form Fee Attached Amendment/Reply After Final Affidavits/declaration(s) Extension of Time Request Express Abandonment Request Information Disclosure Statement		CLOSURES (Check all that and an incomplete content of the content		ddress	After Allowance Communication to TC Appeal Communication to Board of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) Proprietary Information Status Letter X Other Enclosure(s) (please Identify below): Request for Corrected Filing Receipt and attachments (6 pages) Return Receipt Postcard	
Certified Copy of Priority Document(s) Reply to Missing Parts/ Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53		Remarks CUSTOMER NO. 25225				
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm Name	MORRISON & FOERSTER LLP					
Signature Printed name	Elizaboth Cany Mullin					
Date	Elizabeth Cary Miller Reg. No. 154 709					
October 19, 2006					54,708	
I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450. Dated: October						

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the U.S. Postal Service on the date shown below with sufficient postage as First Class Mail, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: October 19

Signature:

(Diane Blevins)

Docket No.: 613242000800

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Patent Application of: Matthias WIESNER et al.

. 2006

Application No.: 10/539,256

Confirmation No.:

Filed: (Int'l) November 25, 2003

Art Unit: 1626

For: ASIMADOLINE DERIVATIVES

Examiner: S. Young

COMPRISING COVALENTLY BONDED

ACIDS

REQUEST FOR CORRECTED FILING RECEIPT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Applicant hereby requests that a corrected Filing Receipt be issued in the aboveidentified patent application. The official Filing Receipt received by Applicant, a copy of which is attached hereto, has an error in the title and should be corrected as follows:

The title of the subject application as listed above should read as follows:

--DERIVATIVES OF ASIMADOLINE WITH COVALENTLY BONDED ACIDS-

Both the English translation of PCT/EP2003/013206 (International Publication No. WO 2004/054970 A1 -a copy of the first page is attached hereto) and the application as filed reflect the aforementioned title. Also attached is a copy of the Official Filing Receipt with the change indicated in red

Docket No.: 613242000800

Applicant requests that all pertinent U.S. Patent and Trademark Office records relating to the subject application be changed to reflect this correction.

Respectfully submitted,

Elizabeth Cary Miller

Registration No.: 54,708 MORRISON & FOERSTER LLP 12531 High Bluff Drive, Suite 100

San Diego, California 92130-2040

(858) 314-7717

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 1 July 2004 (01.07.2004)

PCT

(10) International Publication Number: WO 2004/054970 A1

(51) International Patent Classification⁷: A61K 31/40

C07D 207/12,

(21) International Application Number:

PCT/EP2003/013206

(22) International Filing Date:

25 November 2003 (25.11.2003)

(25) Filing Language:

German

(26) Publication Language:

German

(30) Priority Data:

102 59 245.4

17 December 2002 (17.12.2002) DE

o) DE

- (71) Applicant (for all designated States except US): MERCK PATENT GMBH [DE/DE]; Frankfurter Strasse 250, 64293 Darmstadt (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): WIESNER, Matthias [DE/DE]; Buchenweg 73, 55128 Mainz (DE). SEYFRIED, Christoph [DE/DE]; Mathildenstrasse 6, 64342 Seeheim-Jugenheim (DE).
- (74) Common Representative: MERCK PATENT GMBH; Frankfurter Strasse 250, 64293 Darmstadt (DE).

- (81) Designated states (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated states (regional): ARIPO Patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DERIVATIVES OF ASIMADOLINE WITH COVALENTLY BONDED ACIDS

(57) Abstract: The present invention relates to derivatives of N-methyl-N-[(1S)-1-phenyl-2-((3S)-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide with covalently bonded acids, and to the salts, solvates and prodrugs thereof, to the derivatives as medicaments, to the use of these derivatives for the preparation of a medicament, to the use of these derivatives for the preparation of a pharmaceutical composition, to a process for the preparation of the said pharmaceutical compositions, to pharmaceutical compositions obtainable by this process, and to a process for the treatment of diseases which comprises the administration of the said pharmaceutical composition.

IND CLMS



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
PO. Box 1430 L. F. N. WILLIAM STATES

O. Box 1450 LE.N. VIII L. Alexandria, Virginia 22313-1450 www.uspko.gov

EXCING OR 371 ATTY.DOCKET NO DRAWINGS **TOT CLMS** ART UNIT FIL FEE REC'D APPL NO. (c) DATE **MERCK-3023** 1150 06/16/2005 1614 10/539,256

23 **CONFIRMATION NO. 2422**

23599 MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. **SUITE 1400** ARLINGTON, VA 22201



FILING RECEIPT *OC000000018139547*

Date Mailed: 03/02/2006

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Matthias Wiesner, Seeheim-Jugenheim, GERMANY; Christoph Seyfried, Seeheim-Jugenheim, GERMANY;

Power of Attorney: The patent practitioners associated with Customer Number 23599.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/EP03/13206 11/25/2003

Foreign Applications

EUROPEAN PATENT OFFICE (EPO) 10259245.4 12/17/2002

Projected Publication Date: 06/08/2006

Non-Publication Request: No

Early Publication Request: No

Derivatives of Asimadoline with Constantly

Asimadoline with Constantly Bonded -Asimadaline derivatives comprising covalently bonded acids

RECEIVE

MAR 2 3 2006

I.P. DEPT. FOLEY & LARDNER

Acid 5



Title

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process simplifies the filing of patent applications on the same invention in member countries, but does not result in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at http://www.uspto.gov/web/offices/pac/doc/general/index.html.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, http://www.stopfakes.gov. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject

matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).